Clinical Trials Browser

Phase 1 × Glioma × Specimen Handling × Clear all

Glioma

NCT02359565 2026-04-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT06964737 2025-10-29

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Phase 1 Recruiting

30 enrolled

CNS

Glioma

NCT06942104 2025-07-18

Imaging of Solid Tumors Using 18F-TRX

Phase 1 Recruiting

56 enrolled

CNSGenitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Glioma, Neoplasm Metastasis, Prostatic Neoplasms

NCT03598244 2025-04-20

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Phase 1 Active not recruiting

41 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Medulloblastoma, Central Nervous System Neoplasms

NCT05773664 2024-09-19

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

Phase 1 Withdrawn

CNS

Glioblastoma, Glioma

Clinical Trials

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Imaging of Solid Tumors Using 18F-TRX

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma